Baidu Biomap, the Chinese biocomputing platform enterprise, has just completed a round of financing of 100 million US dollars, led by GGV capital. Robin Li, the founder of Baidu, continues to invest more. This round of financing will be mainly used for technology R & D and talent introduction. After this round of financing, the company will further strengthen the construction of its biological computing engine, continue research and development in the fields of multi-omics technology, high-throughput experimental technology, protein computing technology, and high-performance biological computing technology, strengthen the introduction of talents, and promote its first batch of drug R & D pipelines to a new stage.
